{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:21:29Z","timestamp":1793863289571,"version":"4.6.1"},"reference-count":101,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jjcc.2021.08.026","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T07:28:07Z","timestamp":1631258887000},"page":"79-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"title":["Venous thromboembolism: Recent advancement and future perspective"],"prefix":"10.1016","volume":"79","author":[{"given":"Yugo","family":"Yamashita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2021.08.026_bib0001","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1160\/TH07-03-0212","article-title":"Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality","volume":"98","author":"Cohen","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0002","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.chest.2016.02.638","article-title":"Analysis of national trends in admissions for pulmonary embolism","volume":"150","author":"Smith","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0003","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jacc.2015.10.060","article-title":"Trends in the management and outcomes of acute pulmonary embolism: analysis from the RIETE registry","volume":"67","author":"Jimenez","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0004","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.thromres.2021.06.008","article-title":"Investigators CVR and Investigators R. Difference between Japanese and White patients with acute pulmonary embolism","volume":"204","author":"Yamashita","year":"2021","journal-title":"Thromb Res."},{"key":"10.1016\/j.jjcc.2021.08.026_bib0005","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1160\/TH17-02-0134","article-title":"Incidence of venous thromboembolism in Asian populations: a systematic review","volume":"117","author":"Lee","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0006","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1538-7836.2010.04108.x","article-title":"Incidence of venous thromboembolism in Korea: from the Health Insurance Review and Assessment Service database","volume":"9","author":"Jang","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0007","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/j.1538-7836.2010.03873.x","article-title":"Incidence and cumulative recurrence rates of venous thromboembolism in the Taiwanese population","volume":"8","author":"Lee","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0008","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1253\/circj.CJ-17-1128","article-title":"Anticoagulation therapy for venous thromboembolism in the real world- from the COMMAND VTE registry","volume":"82","author":"Yamashita","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0009","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0010","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"Buller","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0011","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0012","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1160\/TH16-07-0509","article-title":"Reasons for the persistent incidence of venous thromboembolism","volume":"117","author":"Heit","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0013","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1160\/TH13-09-0793","article-title":"Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer","volume":"112","author":"Martinez","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0014","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/archinte.164.20.2260","article-title":"Venous thromboembolism according to age: the impact of an aging population","volume":"164","author":"Stein","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0015","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","article-title":"Epidemiology of venous thromboembolism","volume":"12","author":"Heit","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0016","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jjcc.2015.03.012","article-title":"Current management of venous thromboembolism in Japan: Current epidemiology and advances in anticoagulant therapy","volume":"66","author":"Nakamura","year":"2015","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0017","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014582","article-title":"Temporal trends in the practice pattern for venous thromboembolism in Japan: insight from JROAD-DPC","volume":"9","author":"Yamashita","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0018","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1161\/CIRCULATIONAHA.107.726232","article-title":"Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry","volume":"117","author":"Laporte","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0019","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S0140-6736(98)07534-5","article-title":"Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER)","volume":"353","author":"Goldhaber","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0020","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0021","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/CIR.0b013e318214914f","article-title":"Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association","volume":"123","author":"Jaff","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0022","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0023","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(11)60824-6","article-title":"Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial","volume":"378","author":"Aujesky","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0024","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010324","article-title":"Prognostic models in acute pulmonary embolism: a systematic review and meta-analysis","volume":"6","author":"Elias","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0025","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/archinte.166.2.169","article-title":"A prediction rule to identify low-risk patients with pulmonary embolism","volume":"166","author":"Aujesky","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0026","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1160\/TH12-07-0466","article-title":"Huisman MV and Hestia Study I. Comparison of two methods for selection of out of hospital treatment in patients with acute pulmonary embolism","volume":"109","author":"Zondag","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0027","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1164\/rccm.200506-862OC","article-title":"Derivation and validation of a prognostic model for pulmonary embolism","volume":"172","author":"Aujesky","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0028","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archinternmed.2010.199","article-title":"Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism","volume":"170","author":"Jimenez","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0029","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1183\/09031936.00070110","article-title":"The shock index and the simplified PESI for identification of low-risk patients with acute pulmonary embolism","volume":"37","author":"Sam","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0030","first-page":"262","article-title":"Validation of simplified PESI score for identification of low-risk patients with pulmonary embolism: from the COMMAND VTE registry","volume":"9","author":"Yamashita","year":"2020","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0031","doi-asserted-by":"crossref","first-page":"706","DOI":"10.12788\/jhm.2961","article-title":"Cardiac troponins in low-risk pulmonary embolism patients: a systematic review and meta-analysis","volume":"13","author":"Darwish","year":"2018","journal-title":"J Hosp Med"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0032","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1164\/rccm.200803-459OC","article-title":"Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis","volume":"178","author":"Klok","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0033","doi-asserted-by":"crossref","first-page":"R103","DOI":"10.1186\/cc10119","article-title":"The prognostic value of markers of right ventricular dysfunction in pulmonary embolism: a meta-analysis","volume":"15","author":"Coutance","year":"2011","journal-title":"Crit Care"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0034","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S0735-1097(97)00319-7","article-title":"Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry","volume":"30","author":"Kasper","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0035","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0735-1097(92)90472-Y","article-title":"Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism","volume":"19","author":"Meyer","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0036","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1161\/01.CIR.0000137826.09715.9C","article-title":"Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials","volume":"110","author":"Wan","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0037","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/eurheartj\/ehu218","article-title":"Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis","volume":"36","author":"Marti","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0038","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa1302097","article-title":"Fibrinolysis for patients with intermediate-risk pulmonary embolism","volume":"370","author":"Meyer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0039","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s11239-019-01913-x","article-title":"Thrombolysis with tissue plasminogen activator in patients with acute pulmonary embolisms in the real world: from the COMMAND VTE registry","volume":"48","author":"Nishimoto","year":"2019","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0040","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.amjcard.2012.09.027","article-title":"Moderate pulmonary embolism treated with thrombolysis (from the \"MOPETT\" Trial)","volume":"111","author":"Sharifi","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0041","doi-asserted-by":"crossref","first-page":"e774","DOI":"10.1161\/CIR.0000000000000707","article-title":"Interventional therapies for acute pulmonary embolism: current status and principles for the development of novel evidence: a scientific statement from the American Heart Association","volume":"140","author":"Giri","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0042","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/jth.13564","article-title":"Inferior vena cava filters","volume":"15","author":"Duffett","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0043","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/archinte.164.14.1541","article-title":"Twenty-one-year trends in the use of inferior vena cava filters","volume":"164","author":"Stein","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0044","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJM199802123380701","article-title":"A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group","volume":"338","author":"Decousus","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0045","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/CIRCULATIONAHA.104.512834","article-title":"Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study","volume":"112","author":"Group","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0046","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/jama.2015.3780","article-title":"Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial","volume":"313","author":"Mismetti","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2020.09.002","article-title":"Long-term effects of non-retrieved inferior vena cava filters on recurrences of venous thromboembolism in cancer and non-cancer patients: From the COMMAND VTE registry","volume":"82","author":"Takase","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0048","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1538-7836.2005.01330.x","article-title":"Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence","volume":"3","author":"Palareti","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0049","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1182\/blood-2018-04-791541","article-title":"Testing and monitoring direct oral anticoagulants","volume":"132","author":"Connors","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0050","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0051","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","article-title":"Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis","volume":"129","author":"Schulman","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0052","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"Hokusai","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0053","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0054","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12959-015-0035-3","article-title":"Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism - the J-EINSTEIN DVT and PE program","volume":"13","author":"Yamada","year":"2015","journal-title":"Thromb J"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0055","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1253\/circj.CJ-15-0195","article-title":"Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J study)","volume":"79","author":"Nakamura","year":"2015","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0056","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1111\/jth.13055","article-title":"Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial","volume":"13","author":"Nakamura","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0057","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi-Ros","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0058","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0059","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.ejca.2012.10.021","article-title":"Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases","volume":"49","author":"Walker","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0060","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0061","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0062","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0063","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0064","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0065","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0066","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0067","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1253\/circj.CJ-20-0084","article-title":"Direct oral anticoagulant therapy for cancer-associated venous thromboembolism in routine clinical practice","volume":"84","author":"Ogino","year":"2020","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0068","article-title":"Prognostic effect of incidental pulmonary embolism on long-term mortality in cancer patients","author":"Nishikawa","year":"2021","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0069","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.thromres.2018.02.144","article-title":"Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis","volume":"173","author":"Li","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0070","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1253\/circj.CJ-20-0223","article-title":"Risk factors for major bleeding during anticoagulation therapy in cancer-associated venous thromboembolism- from the COMMAND VTE registry","volume":"84","author":"Nishimoto","year":"2020","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0071","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1503\/cmaj.080493","article-title":"Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy","volume":"179","author":"Rodger","year":"2008","journal-title":"CMAJ"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0072","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1161\/CIRCULATIONAHA.109.925214","article-title":"Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model","volume":"121","author":"Eichinger","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0073","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1538-7836.2012.04735.x","article-title":"Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH)","volume":"10","author":"Tosetto","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0074","doi-asserted-by":"crossref","first-page":"l4363","DOI":"10.1136\/bmj.l4363","article-title":"Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis","volume":"366","author":"Khan","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0075","doi-asserted-by":"crossref","first-page":"893","DOI":"10.7326\/0003-4819-139-11-200312020-00007","article-title":"Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis","volume":"139","author":"Linkins","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0076","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1160\/TH08-03-0193","article-title":"Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE registry","volume":"100","author":"Ruiz-Gimenez","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0077","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1183\/13993003.00280-2016","article-title":"Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment","volume":"48","author":"Klok","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0078","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/jth.14691","article-title":"Validation of the VTE-BLEED score\u2019s long-term performance for major bleeding in patients with venous thromboembolisms: from the COMMAND VTE registry","volume":"18","author":"Nishimoto","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0079","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0080","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0081","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.thromres.2017.06.012","article-title":"Trends in admission rates and in-hospital stay for venous thromboembolism","volume":"156","author":"Mansour","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0082","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1160\/TH16-01-0004","article-title":"Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the HoT-PE trial","volume":"116","author":"Barco","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0083","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.chest.2019.08.2206","article-title":"Usefulness of simplified pulmonary embolism severity index score for identification of patients with low-risk pulmonary embolism and active cancer: from the COMMAND VTE registry","volume":"157","author":"Yamashita","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0084","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/jth.12883","article-title":"Diagnosis and treatment of incidental venous thromboembolism in cancer patients: guidance from the SSC of the ISTH","volume":"13","author":"Di Nisio","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0085","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/j.1538-7836.2010.03938.x","article-title":"Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications. A systematic review and meta-analysis of the management outcome studies","volume":"8","author":"Carrier","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0086","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/acem.13399","article-title":"Systematic review and meta-analysis of outcomes of patients with subsegmental pulmonary embolism with and without anticoagulation treatment","volume":"25","author":"Bariteau","year":"2018","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0088","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/bjs.10152","article-title":"Systematic review of the complications following isolated calf deep vein thrombosis","volume":"103","author":"Garry","year":"2016","journal-title":"Br J Surg"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0089","doi-asserted-by":"crossref","first-page":"227","DOI":"10.5694\/mja2.50004","article-title":"New guidelines from the Thrombosis and Haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism","volume":"210","author":"Tran","year":"2019","journal-title":"Med J Aust"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0090","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/jth.13677","article-title":"Anticoagulation in patients with isolated distal deep vein thrombosis: a meta-analysis","volume":"15","author":"Franco","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0091","doi-asserted-by":"crossref","first-page":"e556","DOI":"10.1016\/S2352-3026(16)30131-4","article-title":"Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial","volume":"3","author":"Righini","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0092","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0140-6736(11)61306-8","article-title":"Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden","volume":"379","author":"Zoller","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0093","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejim.2020.10.017","article-title":"Autoimmune disorders and venous thromboembolism: an update from the COMMAND VTE registry","volume":"84","author":"Yamashita","year":"2021","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0094","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1182\/blood-2013-04-496257","article-title":"Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review","volume":"122","author":"Garcia","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0095","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0096","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0097","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1055\/s-0039-1692439","article-title":"The safety and efficacy of novel agents targeting factors XI and XII in early phase human trials","volume":"45","author":"DeLoughery","year":"2019","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0098","doi-asserted-by":"crossref","first-page":"245","DOI":"10.31083\/j.rcm.2019.04.56","article-title":"Factors IX, XI, and XII: potential therapeutic targets for anticoagulant therapy in atherothrombosis","volume":"20","author":"Rai","year":"2019","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0099","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"Buller","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0100","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/13543776.2020.1705783","article-title":"Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present)","volume":"30","author":"Al-Horani","year":"2020","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.jjcc.2021.08.026_bib0101","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","author":"Verhamme","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S091450872100229X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S091450872100229X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:06:07Z","timestamp":1760274367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S091450872100229X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S091450872100229X"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2021.08.026","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Venous thromboembolism: Recent advancement and future perspective","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2021.08.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Japanese College of Cardiology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}